Impax Laboratories (Nasdaq: IPXL) reported earnings yesterday. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Impax Laboratories whiffed on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share dropped.

Margins dropped across the board.

Revenue details
Impax Laboratories recorded revenue of $128.6 million. The 11 analysts polled by S&P Capital IQ expected to see revenue of $165.1 million on the same basis. GAAP reported sales were 18% higher than the prior-year quarter's $108.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.52. The 11 earnings estimates compiled by S&P Capital IQ forecast $0.45 per share. GAAP EPS of $0.18 for Q1 were 14% lower than the prior-year quarter's $0.21 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 48.7%, 520 basis points worse than the prior-year quarter. Operating margin was 17.5%, 320 basis points worse than the prior-year quarter. Net margin was 9.6%, 320 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $165.6 million. On the bottom line, the average EPS estimate is $0.45.

Next year's average estimate for revenue is $671.4 million. The average EPS estimate is $1.82.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 167 members rating the stock outperform and 11 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Impax Laboratories a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $24.89.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Impax Laboratories the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.